The olfactory changes that appear in early Alzheimer’s disease are primarily deficits in odor identification — the ability to recognize and name a familiar smell — and this impairment affects roughly 85 percent of patients with early-stage Alzheimer’s. What makes this finding so significant is that the smell loss often shows up years before any noticeable memory problems, placing it among the earliest detectable behavioral signs of the disease. A person might walk past a bakery and not register the scent of fresh bread, or fail to notice that milk has gone sour, long before they start forgetting appointments or misplacing keys.
Beyond simple identification, the changes extend to odor discrimination (telling two smells apart) and odor memory (recalling a scent encountered minutes earlier). But identification deficits consistently show the largest effect sizes in clinical studies, making them the most reliable olfactory marker for screening purposes. These smell changes are not random — they are driven by specific pathological processes, particularly tau protein accumulation in olfactory brain circuits, that begin in the earliest stages of Alzheimer’s pathology. This article examines what is actually happening in the brain’s smell-processing regions during early Alzheimer’s, how accurately smell tests can distinguish healthy aging from disease, what structural brain changes underlie the dysfunction, and what clinical tools are being developed to bring olfactory screening into routine medical practice.
Table of Contents
- Why Does Smell Decline Before Memory in Early Alzheimer’s Disease?
- How Accurate Are Smell Tests at Detecting Early Alzheimer’s?
- What Brain Structures Change When Smell Fades in Alzheimer’s?
- What Clinical Smell Tests Are Available for Early Alzheimer’s Screening?
- What Are the Limits and Pitfalls of Using Smell Loss as an Alzheimer’s Marker?
- What New Science Is Revealing About Olfactory Neurons and Neuroinflammation
- Where Olfactory Screening for Alzheimer’s Is Headed
- Conclusion
- Frequently Asked Questions
Why Does Smell Decline Before Memory in Early Alzheimer’s Disease?
The answer lies in the anatomy of where Alzheimer’s pathology begins. Tau protein — one of the two hallmark proteins of the disease — accumulates in the brain’s olfactory structures remarkably early. Research published in neuropathology journals has found that tau pathology is present in the olfactory system in 90.4 percent of Braak stage 4 Alzheimer’s cases, while amyloid plaques appear in only about 9 percent of those same cases at that stage. This means tau is inflicting damage on smell-processing circuits long before amyloid deposits become widespread, and long before the memory centers of the brain are heavily affected. A 2024 study in Nature Communications reinforced this timeline by demonstrating that tau propagation through the brain’s olfactory circuits is directly associated with changes in smell perception during aging. In practical terms, the olfactory bulb and the entorhinal cortex — a gateway between the nose and the hippocampus — are among the first structures to accumulate the toxic protein tangles.
The hippocampus, famous for its role in memory, gets hit later. So a person may lose the ability to identify the scent of cinnamon or gasoline while still performing normally on standard cognitive tests. A 2025 study in Nature Communications added another layer to this understanding. Researchers found that early loss of noradrenergic input from the locus coeruleus to the olfactory bulb coincides with impaired smell in Alzheimer’s mouse models — and critically, this occurs before amyloid plaques even appear. Microglia in the olfactory bulb were found to attack and consume these nerve fibers. When researchers genetically reduced this phagocytic activity, both the nerve fibers and smell function were preserved. This finding suggests that neuroinflammation in the olfactory system is not just a bystander but an active driver of early smell loss.
How Accurate Are Smell Tests at Detecting Early Alzheimer’s?
The diagnostic accuracy of olfactory testing for early Alzheimer’s detection is surprisingly strong. A 2024 study published in Nature Scientific Reports found that odor identification testing achieved an area under the curve (AUC) of 0.908 for differentiating healthy controls from people with prodromal Alzheimer’s disease. To put that in context, an AUC of 1.0 represents a perfect test, and anything above 0.9 is considered excellent. For a test that costs almost nothing and takes five minutes, that level of accuracy is remarkable compared to PET scans costing thousands of dollars or spinal taps that most patients would rather avoid. A separate 2024 meta-analysis published in ScienceDirect confirmed that odor identification shows larger effect sizes than either odor threshold testing (detecting the faintest concentration of a smell) or odor discrimination testing (distinguishing between two different scents) in both MCI and Alzheimer’s populations.
This matters for clinical screening because it tells us which type of smell test to prioritize. Asking someone to identify the smell of a lemon is more diagnostically useful than asking whether they can detect a faint whiff of rose water. However, olfactory testing has important limitations. Smell naturally declines with normal aging, upper respiratory infections can temporarily impair olfaction, and chronic conditions like nasal polyps or a long history of smoking can confound results. A failed smell test in a 75-year-old lifelong smoker means something different than a failed test in a 60-year-old nonsmoker. Olfactory testing is best understood as a screening flag — not a standalone diagnosis — that should prompt further evaluation with cognitive assessments and biomarker testing when results are abnormal.
What Brain Structures Change When Smell Fades in Alzheimer’s?
The structural damage underlying olfactory loss in Alzheimer’s is visible on brain imaging, and it follows a predictable pattern. A 2025 study published in Frontiers in Aging Neuroscience found that patients with mild cognitive impairment and Alzheimer’s disease show reduced gray matter volumes in three key areas: the olfactory bulb, the primary olfactory cortex, and the hippocampus. These reductions are detectable as early as the MCI stage and grow more pronounced as the disease progresses to dementia. Consider the olfactory bulb as the brain’s first relay station for smell signals arriving from the nose. When this structure shrinks, fewer signals get processed. The primary olfactory cortex, which interprets those signals, also loses volume.
And the hippocampus — which connects smell to memory and is the reason a scent can transport you back to childhood — deteriorates in parallel. This explains why early Alzheimer’s patients don’t just lose the ability to name a smell; they also lose the emotional and memory associations that make smells meaningful. The smell of pine might register faintly but no longer evoke any recollection of a Christmas tree. Data from the Baltimore Longitudinal Study of Aging, which followed 364 participants over approximately two and a half years, confirmed that loss of olfactory function is closely tied to both the level and the progression of Alzheimer’s neuropathological damage. Participants whose smell declined more rapidly showed greater gray matter volume loss in regions associated with Alzheimer’s disease. A separate 2023 analysis published in Alzheimer’s & Dementia reached a similar conclusion: rapid olfactory decline during aging predicts both dementia onset and gray matter loss in AD-associated brain regions.
What Clinical Smell Tests Are Available for Early Alzheimer’s Screening?
Several validated tools exist, and the choice between them involves tradeoffs between thoroughness and practicality. The University of Pennsylvania Smell Identification Test (UPSIT) is the most widely used in research settings. It consists of 40 scratch-and-sniff items and provides a comprehensive olfactory profile, but it takes 15 to 20 minutes and is most practical in a clinic or lab. The Sniffin’ Sticks test, popular in European clinical settings, evaluates threshold, discrimination, and identification using felt-tip pen–like odor dispensers. For faster screening, the 12-item Brief Smell Identification Test (BSIT) is a validated, non-invasive tool that takes approximately five minutes to complete.
It sacrifices some granularity for speed and accessibility, making it more practical for routine primary care visits where time is limited. The tradeoff is real — the BSIT may miss subtler deficits that the full UPSIT would catch — but for a first-pass screen in a general practice setting, its brevity is an advantage. The newest entry is the Aromha Brain Health Test, developed by researchers at Mass General Brigham and published in Scientific Reports in March 2025. This at-home test uses odor labels printed on a card that participants sniff to assess their ability to discriminate, identify, and remember odors. Early results confirmed that olfactory dysfunction increased with age and was worse among those with MCI. The at-home format removes the need for a clinic visit entirely, which could make olfactory screening feasible at a population level — something no existing tool has achieved.
What Are the Limits and Pitfalls of Using Smell Loss as an Alzheimer’s Marker?
The biggest challenge is specificity. Smell loss is not unique to Alzheimer’s disease. Parkinson’s disease is also strongly associated with olfactory dysfunction, and in fact smell testing is already used as a supporting diagnostic tool for Parkinson’s. Other neurodegenerative conditions, including Lewy body dementia and frontotemporal dementia, can involve olfactory changes as well. A positive result on a smell test tells you something is likely wrong with the brain’s smell-processing circuits, but it cannot tell you which disease is responsible without additional testing. Age-related olfactory decline is another confounder.
Roughly a quarter of adults over 60 have measurable smell impairment that has nothing to do with neurodegeneration. Post-viral olfactory loss — made especially visible during the COVID-19 pandemic — can persist for months or years after the initial infection. Medications, head trauma, and environmental exposures to chemicals or toxins can also damage the olfactory system. A clinician interpreting a smell test result needs the patient’s full medical history to avoid false alarms. There is also the emotional weight of what these tests might reveal. Telling a cognitively healthy 55-year-old that their smell test suggests they may be on a path toward Alzheimer’s raises profound ethical and psychological questions, especially when no disease-modifying treatment can fully halt the progression. Screening tools are only as useful as the clinical pathway they feed into, and the infrastructure for counseling and follow-up after a positive smell screen is still being built.
What New Science Is Revealing About Olfactory Neurons and Neuroinflammation
A 2025 preprint on bioRxiv analyzed olfactory bulb biopsies using single-cell RNA sequencing and identified conserved neuroinflammatory changes — including activated memory T cell states and altered myeloid and olfactory neuron populations — that were detectable even in pre-clinical Alzheimer’s subjects. The activated memory T cell signature was described as a hallmark of pre-clinical disease, raising the possibility that a biopsy of the olfactory mucosa (the tissue lining the upper nose) could one day serve as a window into brain pathology without the need for a lumbar puncture or PET scan.
This is still early-stage research, and olfactory biopsies are not a routine clinical procedure. But the concept is compelling: the nose is the only place where neurons are directly exposed to the outside environment, making them uniquely accessible compared to neurons buried deep in the brain. If validated in larger human studies, this approach could transform how we detect Alzheimer’s at its earliest, pre-symptomatic stages.
Where Olfactory Screening for Alzheimer’s Is Headed
The convergence of cheap smell tests, validated diagnostic accuracy, and deepening understanding of the underlying biology points toward a future where olfactory screening becomes a routine part of aging healthcare — similar to how blood pressure checks became standard decades ago. The Aromha Brain Health Test and tools like it are designed for self-administration at home, which removes the bottleneck of clinic access. Combined with emerging blood-based biomarkers for amyloid and tau, a failed smell test could trigger a simple blood draw rather than an expensive imaging study, creating a practical two-step screening pathway. The key uncertainty is timing.
The science connecting smell loss to Alzheimer’s is robust, but integrating olfactory screening into clinical guidelines requires large prospective validation studies, consensus on cutoff scores adjusted for age and sex, and clear protocols for what happens after a positive screen. The research community is moving quickly — the volume of olfactory-Alzheimer’s studies published in 2024 and 2025 alone is striking — but translating that research into standard clinical practice typically takes years. For now, anyone concerned about their sense of smell, particularly if they notice a decline in their ability to identify familiar odors, should mention it to their physician. It may be nothing. But it may also be one of the earliest signals the brain can send.
Conclusion
Olfactory changes in early Alzheimer’s disease — especially the inability to identify familiar smells — are among the earliest detectable signs of the condition, appearing years before cognitive symptoms become apparent. These deficits are driven by tau pathology and neuroinflammation in the brain’s smell-processing circuits, affect roughly 85 percent of early-stage patients, and can be measured with simple, low-cost tests that achieve diagnostic accuracy above 0.9 AUC. The structural brain changes underlying these deficits, including reduced gray matter volume in the olfactory bulb, olfactory cortex, and hippocampus, are measurable on imaging and worsen as the disease progresses.
For families navigating early signs of cognitive change, paying attention to smell is a practical step that costs nothing. If a loved one stops noticing the scent of coffee brewing, can no longer tell the difference between vanilla and almond extract, or fails to react to spoiled food, these are worth documenting and discussing with a doctor. Olfactory testing will not replace comprehensive Alzheimer’s diagnostics, but it is rapidly earning its place as a frontline screening tool — accessible, non-invasive, and grounded in decades of neuroscience research confirming that the nose knows something before the rest of the brain catches up.
Frequently Asked Questions
Can a simple smell test really detect Alzheimer’s disease early?
Smell tests cannot diagnose Alzheimer’s on their own, but odor identification testing has achieved an AUC of 0.908 in differentiating healthy individuals from those with prodromal Alzheimer’s. A failed smell test should be considered a prompt for further evaluation, not a diagnosis by itself.
How many years before memory loss does smell decline begin in Alzheimer’s?
Research shows that impairment in odor identification precedes detectable cognitive impairment by several years, occurring even before the stages of subjective cognitive decline and mild cognitive impairment. The exact number of years varies between individuals.
Is smell loss always a sign of Alzheimer’s disease?
No. Smell loss can result from normal aging, Parkinson’s disease, post-viral damage (including from COVID-19), nasal polyps, head injuries, medications, and other causes. Alzheimer’s-related smell loss tends to specifically affect odor identification and worsens over time alongside other subtle changes.
What type of smell test is most useful for Alzheimer’s screening?
Odor identification tests — where you are asked to name or match a smell — show larger effect sizes than odor threshold or odor discrimination tests. Common validated tools include the University of Pennsylvania Smell Identification Test (UPSIT), the 12-item Brief Smell Identification Test (BSIT), and the Sniffin’ Sticks test.
What is the Aromha Brain Health Test?
Developed by Mass General Brigham researchers and published in March 2025, it is an at-home smell test where participants sniff odor labels on a card to assess their ability to discriminate, identify, and remember odors. Early results confirmed that olfactory dysfunction worsened with age and was more pronounced among those with mild cognitive impairment.
Why does tau protein damage smell before memory?
Tau pathology accumulates in olfactory brain structures very early in the disease process. In Braak stage 4 Alzheimer’s cases, tau was found in the olfactory system in over 90 percent of cases, while amyloid was present in only 9 percent. The olfactory bulb and entorhinal cortex are hit before the hippocampus, which is why smell fades before memory noticeably declines.
